Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 12Stomach Neoplasms 10Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Advanced Solid Tumor 9Carcinoma, Hepatocellular 7Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumor 4Melanoma 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Neoplasms 3Lymphoma 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2

Interventions

Gemcitabine 210-propargyl-10-deazaaminopterin 2tislelizumab 1ontuxizumab 1glofitamab 1enasidenib 1duvelisib 1brincidofovir 1belinostat 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Sensitivity and Specificity 1MLN 8237 1MAC-ST-001 1Folic Acid 1Fentanyl 1Fenretinide 1Commerce 1Bendamustine Hydrochloride 1(N(1),N(12))bis(ethyl)-6,7-dehydrospermine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immunoblastic Lymphadenopathy × tislelizumab × Clear all
NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

BeiGene

Phase 2 Completed
77 enrolled 20 charts
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡